MedTrace Logo

LY2189265 and Atorvastatin Interaction Study

NCT01250834 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2014-10-08

Study results available
· View outcomes & findings →

Summary

This study will assess if giving LY2189265 at the same time as atorvastatin affects how the body absorbs atorvastatin.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Atorvastatin

Administered orally.

BIOLOGICAL

LY2189265

Administered subcutaneously.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01250834 on ClinicalTrials.gov